FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

On December 19, 2018, the U.S. Food and Drug Administration (FDA) granted approval to olaparib monotherapy for first‐line maintenance treatment of BRCA‐mutated (BRCAm) advanced ovarian cancer and, on May 8, 2020, expanded the indication of olaparib to include its use in combination with bevacizumab...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Arora, Shaily, Balasubramaniam, Sanjeeve, Zhang, Hui, Berman, Tara, Narayan, Preeti, Suzman, Daniel, Bloomquist, Erik, Tang, Shenghui, Gong, Yutao, Sridhara, Rajeshwari, Turcu, Francisca Reyes, Chatterjee, Deb, Saritas‐Yildirim, Banu, Ghosh, Soma, Philip, Reena, Pathak, Anand, Gao, Jennifer J., Amiri‐Kordestani, Laleh, Pazdur, Richard, Beaver, Julia A.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Regulatory Issues: FDA
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794199/
https://ncbi.nlm.nih.gov/pubmed/33017510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13551
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares